M. Blankenburg

发表

Cost impact of prospective HLA-B*5701-screening prior to abacavir/lamivudine fixed dose combination use in Germany

E. Wolf, M. Blankenburg, J. Bogner, 2010, European journal of medical research.

PMD2 A META-ANALYSIS OF BIOMARKERS AND DIAGNOSTIC IMAGING IN ALZHEIMER'S DISEASE

S. Sullivan, M. Blankenburg, L. Bloudek, 2011 .

Adherence to Chronic Kidney Disease Screening Guidelines Among Patients With Type 2 Diabetes in a US Administrative Claims Database.

L. Fried, C. Kovesdy, N. Petruski-Ivleva, 2021, Mayo Clinic proceedings.

Disease characteristics and outcomes in patients with chronic kidney disease and type 2 diabetes: a matched cohort study of spironolactone users and non-users

A. Fett, C. Kovesdy, M. Blankenburg, 2020, BMC Nephrology.

Angiography for Diagnosing Peripheral Arterial Occlusive Disease - A Technical, Clinical and Cost Comparison of Contrast-enhanced Magnetic Resonance Angiography and Unenhanced Magnetic Resonance Imaging Techniques with a Focus on Fresh Blood Imaging

M. Rohrer, C. Schwenke, M. Blankenburg, 2010 .

Treatment of irritable bowel syndrome with Lacteol Fort: a randomized, double-blind, cross-over trial.

M. Gershwin, M. Blankenburg, T. Prindiville, 1996, The American journal of gastroenterology.

Evaluation of the health economic impact of initial diagnostic modality selection in patients suspected of having HCC in China and the USA

G. Knobloch, M. Blankenburg, Guanyi Jin, 2022, Journal of medical economics.

Patient characteristics and initiation of mineralocorticoid receptor antagonists in patients with chronic kidney disease in routine clinical practice in the US: a retrospective cohort study

A. Fett, M. Blankenburg, A. Gay, 2019, BMC Nephrology.

Review and meta-analysis of biomarkers and diagnostic imaging in Alzheimer's disease.

Sean D Sullivan, S. Sullivan, M. Blankenburg, 2011, Journal of Alzheimer's disease : JAD.

Annual health care resource utilization and cost among type 2 diabetes patients with newly recognized chronic kidney disease within a large U.S. administrative claims database.

L. Fried, C. Kovesdy, N. Petruski-Ivleva, 2020, Journal of managed care & specialty pharmacy.

Chronic kidney disease progression among patients with type 2 diabetes identified in US administrative claims: a population cohort study

L. Fried, C. Kovesdy, N. Petruski-Ivleva, 2020, Clinical kidney journal.

Florbetaben PET in the Early Diagnosis of Alzheimer's Disease: A Discrete Event Simulation to Explore Its Potential Value and Key Data Gaps

Kelly Cho, Denis Getsios, Elizabeth Lawler, 2012, International journal of Alzheimer's disease.

Cardiovascular and Renal Outcomes in Patients with Type-2 Diabetes and Chronic Kidney Disease Identified in a United States Administrative Claims Database: A Population Cohort Study

L. Fried, C. Kovesdy, N. Petruski-Ivleva, 2021, Nephron.

To pay or not to pay for artificial intelligence applications in radiology

M. Blankenburg, D. Subramanian, O. Butler, 2023, NPJ digital medicine.

Understanding the Suitability of Cystic Fibrosis-Specific Clinical Outcome Assessments For Clinical Trials and to Support Medical Product Labeling

T. Willgoss, H. Kitchen, A. Trigg, 2015 .

Economic evaluation of supplemental breast cancer screening modalities to mammography or digital breast tomosynthesis in women with heterogeneously and extremely dense breasts and average or intermediate breast cancer risk in US healthcare

G. Newstead, M. Blankenburg, Ö. Åkerborg, 2023, Journal of medical economics.

Central Nervous System Drug Consumption Depending on the Time between Symptom Onset and the Diagnosis of Alzheimer’s Disease: An Analysis by the Registry of Dementias of Girona

L. Calvó-Perxas, J. Vilalta-Franch, J. Garre-Olmo, 2012, Dementia and Geriatric Cognitive Disorders.

Performance of Supplemental Imaging Modalities for Breast Cancer in Women With Dense Breasts: Findings From an Umbrella Review and Primary Studies Analysis.

G. Newstead, M. Blankenburg, A. Caleyachetty, 2023, Clinical breast cancer.